Header Logo

Connection

JAFFER A AJANI to Combined Modality Therapy

Back to Details
This is a "connection" page, showing publications JAFFER A AJANI has written about Combined Modality Therapy.
JAFFER A AJANI
Connection Strength
4.483
Combined Modality Therapy
  1. Therapy of localized esophageal cancer: it is time to reengineer our investigative strategies. Onkologie. 2008 Jul; 31(7):360-1.
    View in: PubMed
    Score: 0.142
  2. Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go? Expert Opin Pharmacother. 2022 Dec; 23(17):1893-1902.
    View in: PubMed
    Score: 0.096
  3. Intraperitoneal therapy for gastric cancer peritoneal carcinomatosis. Expert Rev Clin Pharmacol. 2022 Jan; 15(1):43-49.
    View in: PubMed
    Score: 0.091
  4. Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone? Chin Clin Oncol. 2021 Jun; 10(3):32.
    View in: PubMed
    Score: 0.084
  5. Recent advances in treating oesophageal cancer. F1000Res. 2020; 9.
    View in: PubMed
    Score: 0.083
  6. A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2021 Jan; 28(1):258-264.
    View in: PubMed
    Score: 0.081
  7. Immunotherapy for esophageal cancer: a 2019 update. Immunotherapy. 2020 02; 12(3):203-218.
    View in: PubMed
    Score: 0.080
  8. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883.
    View in: PubMed
    Score: 0.076
  9. YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019 04 01; 25(7):2264-2277.
    View in: PubMed
    Score: 0.073
  10. Recent advances in the management of gastric adenocarcinoma patients. F1000Res. 2018; 7.
    View in: PubMed
    Score: 0.072
  11. Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. Oncology. 2018; 95(2):81-90.
    View in: PubMed
    Score: 0.070
  12. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.067
  13. Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Ann Surg Oncol. 2017 Oct; 24(11):3338-3344.
    View in: PubMed
    Score: 0.067
  14. 101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. Oncology. 2017; 93(4):243-248.
    View in: PubMed
    Score: 0.066
  15. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 01; 3:17036.
    View in: PubMed
    Score: 0.066
  16. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec; 140(12):1345-1363.
    View in: PubMed
    Score: 0.063
  17. Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Ann Surg Oncol. 2017 Aug; 24(8):2291-2301.
    View in: PubMed
    Score: 0.063
  18. Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Ann Surg Oncol. 2016 06; 23(6):1948-55.
    View in: PubMed
    Score: 0.060
  19. A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. J Natl Compr Canc Netw. 2016 02; 14(2):173-9.
    View in: PubMed
    Score: 0.060
  20. Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. Oncology. 2015; 89(6):305-10.
    View in: PubMed
    Score: 0.059
  21. Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. Oncology. 2015; 88(6):332-6.
    View in: PubMed
    Score: 0.056
  22. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014 Aug; 12(8):1139-44.
    View in: PubMed
    Score: 0.054
  23. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013; 85(4):204-7.
    View in: PubMed
    Score: 0.051
  24. Results of the baseline positron emission tomography can customize therapy of localized esophageal adenocarcinoma patients who achieve a clinical complete response after chemoradiation. Ann Oncol. 2013 Nov; 24(11):2854-9.
    View in: PubMed
    Score: 0.051
  25. A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2013 Nov; 24(11):2844-9.
    View in: PubMed
    Score: 0.051
  26. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013 May 01; 11(5):531-46.
    View in: PubMed
    Score: 0.050
  27. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting. Dis Esophagus. 2013 Sep-Oct; 26(7):708-15.
    View in: PubMed
    Score: 0.049
  28. Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. Ann Oncol. 2013 May; 24(5):1262-6.
    View in: PubMed
    Score: 0.048
  29. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.047
  30. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012 Oct; 23(10):2638-2642.
    View in: PubMed
    Score: 0.047
  31. Therapy: localized gastric cancer--a CLASSIC shift in the paradigm? Nat Rev Gastroenterol Hepatol. 2012 Mar 06; 9(4):194-5.
    View in: PubMed
    Score: 0.046
  32. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):830-87.
    View in: PubMed
    Score: 0.044
  33. Modern approaches to localized cancer of the esophagus. J Natl Compr Canc Netw. 2011 Aug 01; 9(8):902-11.
    View in: PubMed
    Score: 0.044
  34. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67.
    View in: PubMed
    Score: 0.043
  35. An expert opinion on esophageal cancer therapy. Expert Opin Pharmacother. 2011 Feb; 12(2):225-39.
    View in: PubMed
    Score: 0.042
  36. Combined modality therapy of cT2N0M0 esophageal cancer: the University of Texas M. D. Anderson Cancer Center experience. Cancer. 2011 Mar 01; 117(5):925-30.
    View in: PubMed
    Score: 0.042
  37. Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. Ann Thorac Surg. 2010 Sep; 90(3):892-8; discussion 898-9.
    View in: PubMed
    Score: 0.041
  38. In the ring with a raging bull: unresectable localized esophageal carcinoma. Onkologie. 2010; 33(5):220-1.
    View in: PubMed
    Score: 0.040
  39. Resectable esophageal cancer: surgery as primary therapy is not the answer, but then, what is and why? J Clin Oncol. 2010 May 20; 28(15):e243-4; author reply e245.
    View in: PubMed
    Score: 0.040
  40. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010 Apr 01; 116(7):1656-63.
    View in: PubMed
    Score: 0.040
  41. Multimodality approaches to localized gastric cancer. J Natl Compr Canc Netw. 2010 Apr; 8(4):417-25.
    View in: PubMed
    Score: 0.040
  42. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy? J Natl Compr Canc Netw. 2010 Jan; 8(1):135-44.
    View in: PubMed
    Score: 0.039
  43. Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci. 2010 Apr; 55(4):1098-105.
    View in: PubMed
    Score: 0.038
  44. Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer. 2009 Feb 01; 115(3):624-30.
    View in: PubMed
    Score: 0.037
  45. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. J Clin Oncol. 2009 Mar 01; 27(7):1116-21.
    View in: PubMed
    Score: 0.037
  46. New pharmacological developments in the treatment of hepatocellular cancer. Drugs. 2009; 69(18):2533-40.
    View in: PubMed
    Score: 0.037
  47. Chemotherapy and radiotherapy resistance: complexity, reality, and promise. J Clin Oncol. 2009 Jan 01; 27(1):162-3; author reply 163.
    View in: PubMed
    Score: 0.037
  48. Therapy-induced expression of NF-kappaB portends poor prognosis in patients with localized esophageal cancer undergoing preoperative chemoradiation. Dis Esophagus. 2009; 22(2):127-32.
    View in: PubMed
    Score: 0.036
  49. Adenocarcinoma of the lower esophagus with Barrett's esophagus or without Barrett's esophagus: differences in patients' survival after preoperative chemoradiation. Dis Esophagus. 2009; 22(1):32-41.
    View in: PubMed
    Score: 0.036
  50. Esophageal cancer. J Natl Compr Canc Netw. 2008 Oct; 6(9):818-49.
    View in: PubMed
    Score: 0.036
  51. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. Cancer. 2008 Sep 15; 113(6):1302-8.
    View in: PubMed
    Score: 0.036
  52. Molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation. Br J Cancer. 2008 Oct 07; 99(7):1195; author reply 1196.
    View in: PubMed
    Score: 0.036
  53. Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol. 2008 Oct 01; 26(28):4551-6.
    View in: PubMed
    Score: 0.035
  54. Upper gastrointestinal tumors: current status and future perspectives. Expert Rev Anticancer Ther. 2008 Jun; 8(6):975-91.
    View in: PubMed
    Score: 0.035
  55. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23; 299(16):1914-21.
    View in: PubMed
    Score: 0.035
  56. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens? J Clin Oncol. 2007 Sep 20; 25(27):4315-6.
    View in: PubMed
    Score: 0.034
  57. Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer. 2007 Sep 01; 110(5):989-95.
    View in: PubMed
    Score: 0.033
  58. Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol. 2006 Dec; 33(6 Suppl 11):S2-5.
    View in: PubMed
    Score: 0.032
  59. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):328-47.
    View in: PubMed
    Score: 0.030
  60. Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006 Apr; 4(4):350-66.
    View in: PubMed
    Score: 0.030
  61. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2006 Apr; 4(4):375-82.
    View in: PubMed
    Score: 0.030
  62. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006 Feb 10; 24(5):748-54.
    View in: PubMed
    Score: 0.030
  63. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006 Jan 10; 24(2):259-67.
    View in: PubMed
    Score: 0.030
  64. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer. 2005 Oct 15; 104(8):1620-6.
    View in: PubMed
    Score: 0.029
  65. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev Anticancer Ther. 2005 Aug; 5(4):719-25.
    View in: PubMed
    Score: 0.029
  66. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol. 2005 Jul 01; 23(19):4256-8.
    View in: PubMed
    Score: 0.028
  67. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005 Feb 20; 23(6):1237-44.
    View in: PubMed
    Score: 0.028
  68. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005; 36(2):69-76.
    View in: PubMed
    Score: 0.028
  69. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004 Aug 01; 101(3):518-26.
    View in: PubMed
    Score: 0.027
  70. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004 Jul 15; 22(14):2774-80.
    View in: PubMed
    Score: 0.027
  71. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer. 2004 Jun 01; 100(11):2347-54.
    View in: PubMed
    Score: 0.027
  72. Operate on my stomach cancer? Oh, no--not you, or not yet! J Clin Oncol. 2004 May 01; 22(9):1763-4; author reply 1764-5.
    View in: PubMed
    Score: 0.027
  73. Updated Analysis of a Phase 2 Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Peritoneal Carcinoma from Gastric Cancer. Ann Surg Oncol. 2024 May; 31(5):2824-2825.
    View in: PubMed
    Score: 0.026
  74. Gastric cancer: advances in adjuvant and adjunct therapy. Curr Treat Options Oncol. 2003 Oct; 4(5):413-9.
    View in: PubMed
    Score: 0.026
  75. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003 Aug; 4(8):498-505.
    View in: PubMed
    Score: 0.025
  76. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003; 21(4):223-7.
    View in: PubMed
    Score: 0.024
  77. Report of the American Society for Therapeutic Radiology and Oncology Working Group on the scope of radiation oncology (SCOPE). Int J Radiat Oncol Biol Phys. 2002 Oct 01; 54(2):317-26.
    View in: PubMed
    Score: 0.024
  78. Adjuvant and preoperative chemotherapy for gastric cancer. Curr Oncol Rep. 2002 May; 4(3):222-8.
    View in: PubMed
    Score: 0.023
  79. Therapy of localized gastric cancer: preoperative and postoperative approaches. Ann Oncol. 2002; 13 Suppl 4:7-12.
    View in: PubMed
    Score: 0.023
  80. Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm. J Thorac Cardiovasc Surg. 2022 08; 164(2):433-437.
    View in: PubMed
    Score: 0.022
  81. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001 Jul 15; 92(2):279-86.
    View in: PubMed
    Score: 0.022
  82. Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. J Natl Cancer Inst. 2021 06 01; 113(6):665-679.
    View in: PubMed
    Score: 0.022
  83. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001 Feb; 24(1):91-5.
    View in: PubMed
    Score: 0.021
  84. Gastroesophageal junction adenocarcinoma. Curr Treat Options Oncol. 2000 Dec; 1(5):387-98.
    View in: PubMed
    Score: 0.021
  85. Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. Cancer Sci. 2020 Nov; 111(11):4205-4217.
    View in: PubMed
    Score: 0.021
  86. Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. Ann Surg Oncol. 2020 Dec; 27(13):4963-4969.
    View in: PubMed
    Score: 0.020
  87. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.020
  88. Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. Ann Surg Oncol. 2020 Aug; 27(8):2806-2811.
    View in: PubMed
    Score: 0.020
  89. Small cell carcinoma of the esophagus: the University of Texas M. D. Anderson Cancer Center experience and literature review. Cancer. 2000 Jan 15; 88(2):262-7.
    View in: PubMed
    Score: 0.020
  90. Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). Eur J Cancer. 2019 11; 121:130-143.
    View in: PubMed
    Score: 0.019
  91. Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Ann Surg Oncol. 2020 Feb; 27(2):534-542.
    View in: PubMed
    Score: 0.019
  92. Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. Ann Surg Oncol. 2019 May; 26(5):1394-1400.
    View in: PubMed
    Score: 0.018
  93. Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. Sci Rep. 2018 09 18; 8(1):14006.
    View in: PubMed
    Score: 0.018
  94. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Ann Surg Oncol. 2018 Sep; 25(9):2720-2730.
    View in: PubMed
    Score: 0.018
  95. Current status of new drugs and multidisciplinary approaches in patients with carcinoma of the esophagus. Chest. 1998 Jan; 113(1 Suppl):112S-119S.
    View in: PubMed
    Score: 0.017
  96. Final Results of NRG Oncology RTOG 0246: An?Organ-Preserving Selective Resection Strategy in?Esophageal Cancer Patients Treated with Definitive?Chemoradiation. J Thorac Oncol. 2017 02; 12(2):368-374.
    View in: PubMed
    Score: 0.016
  97. Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Ann Surg Oncol. 2016 Jan; 23(1):156-62.
    View in: PubMed
    Score: 0.014
  98. EUS assessment of response to chemoradiation in esophageal cancer patients. Am J Gastroenterol. 2005 Feb; 100(2):496-7; author reply 497-9.
    View in: PubMed
    Score: 0.014
  99. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer. 1995; 31A(5):665-70.
    View in: PubMed
    Score: 0.014
  100. Therapy of carcinoma of the oesophagus: either attempt it not or succeed. Eur J Cancer. 1995; 31A(5):790-3.
    View in: PubMed
    Score: 0.014
  101. Has combined modality therapy improved the outlook in carcinoma of the esophagus? Oncology (Williston Park). 1994 Sep; 8(9):37-42; discussion 44-5, 50-2, 61.
    View in: PubMed
    Score: 0.014
  102. Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. Dis Colon Rectum. 2014 Aug; 57(8):941-57.
    View in: PubMed
    Score: 0.014
  103. Adjuvant radiotherapy and chemotherapy for biliary and pancreatic cancer. Ann Oncol. 1994; 5 Suppl 3:75-80.
    View in: PubMed
    Score: 0.013
  104. Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2013 Aug 01; 86(5):885-91.
    View in: PubMed
    Score: 0.013
  105. In rectal carcinoma, colostomy or no colostomy: is this the question? J Clin Oncol. 1993 Jan; 11(1):193-4.
    View in: PubMed
    Score: 0.012
  106. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer. 1992; 28A(4-5):880-4.
    View in: PubMed
    Score: 0.011
  107. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. Cancer. 1991 Oct 01; 68(7):1501-6.
    View in: PubMed
    Score: 0.011
  108. Current strategies in the management of locoregional and metastatic gastric carcinoma. Cancer. 1991 Jan 01; 67(1 Suppl):260-5.
    View in: PubMed
    Score: 0.011
  109. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010 Dec 01; 28(34):5061-6.
    View in: PubMed
    Score: 0.010
  110. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 1990 Jul; 8(7):1231-8.
    View in: PubMed
    Score: 0.010
  111. Systemic and regional therapy of advanced islet cell tumors. Gastroenterol Clin North Am. 1989 Dec; 18(4):923-30.
    View in: PubMed
    Score: 0.010
  112. Outcomes with esophageal cancer radiation therapy. J Thorac Oncol. 2009 Jul; 4(7):880-8.
    View in: PubMed
    Score: 0.010
  113. Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancer. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):816-23.
    View in: PubMed
    Score: 0.009
  114. Patterns of care and locoregional treatment outcomes in older esophageal cancer patients: The SEER-Medicare Cohort. Int J Radiat Oncol Biol Phys. 2009 Jun 01; 74(2):482-9.
    View in: PubMed
    Score: 0.009
  115. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008 Sep; 32(9):1404-11.
    View in: PubMed
    Score: 0.009
  116. Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):167-72.
    View in: PubMed
    Score: 0.009
  117. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008; 47(3):421-7.
    View in: PubMed
    Score: 0.009
  118. Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):741-7.
    View in: PubMed
    Score: 0.009
  119. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Jul; 14(7):2010-7.
    View in: PubMed
    Score: 0.008
  120. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007 Feb 01; 13(3):912-9.
    View in: PubMed
    Score: 0.008
  121. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol. 2006 Sep 14; 12(34):5501-8.
    View in: PubMed
    Score: 0.008
  122. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006 Sep 01; 107(5):967-74.
    View in: PubMed
    Score: 0.008
  123. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006 Aug 01; 12(15):4590-7.
    View in: PubMed
    Score: 0.008
  124. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol. 2006 Jun; 1(5):478-86.
    View in: PubMed
    Score: 0.008
  125. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006 Mar 01; 106(5):1017-25.
    View in: PubMed
    Score: 0.008
  126. Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol. 2006 Mar; 1(3):252-9.
    View in: PubMed
    Score: 0.008
  127. Neuroendocrine tumors. J Natl Compr Canc Netw. 2006 Feb; 4(2):102-38.
    View in: PubMed
    Score: 0.008
  128. Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):65-72.
    View in: PubMed
    Score: 0.007
  129. Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):700-8.
    View in: PubMed
    Score: 0.007
  130. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006 Mar 01; 64(3):692-9.
    View in: PubMed
    Score: 0.007
  131. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg. 2005 May; 241(5):810-7; discussion 817-20.
    View in: PubMed
    Score: 0.007
  132. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. Ann Thorac Surg. 2005 May; 79(5):1716-23.
    View in: PubMed
    Score: 0.007
  133. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005 Apr 01; 103(7):1347-55.
    View in: PubMed
    Score: 0.007
  134. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. Clin Cancer Res. 2005 Mar 15; 11(6):2229-36.
    View in: PubMed
    Score: 0.007
  135. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 01; 61(3):656-64.
    View in: PubMed
    Score: 0.007
  136. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004 Dec 01; 60(5):1484-93.
    View in: PubMed
    Score: 0.007
  137. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
    View in: PubMed
    Score: 0.007
  138. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004 Oct 01; 60(2):427-36.
    View in: PubMed
    Score: 0.007
  139. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
    View in: PubMed
    Score: 0.007
  140. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004 Aug; 39(8):e8-10.
    View in: PubMed
    Score: 0.007
  141. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004 May 15; 22(10):1785-96.
    View in: PubMed
    Score: 0.007
  142. Significance of post-chemoradiation biopsy in predicting residual esophageal carcinoma in the surgical specimen. Dis Esophagus. 2004; 17(1):38-43.
    View in: PubMed
    Score: 0.006
  143. Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose-volume histogram parameters. Int J Radiat Oncol Biol Phys. 2003 Dec 01; 57(5):1317-22.
    View in: PubMed
    Score: 0.006
  144. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):120-7.
    View in: PubMed
    Score: 0.006
  145. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer. 2003 Mar 01; 97(5):1195-202.
    View in: PubMed
    Score: 0.006
  146. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002 Jan; 123(1):175-83.
    View in: PubMed
    Score: 0.006
  147. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 06; 345(10):725-30.
    View in: PubMed
    Score: 0.006
  148. Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. Int J Radiat Oncol Biol Phys. 2001; 51(3 Suppl 2):19-27.
    View in: PubMed
    Score: 0.005
  149. Preoperative infusional chemoradiation therapy for stage T3 rectal cancer. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):1025-9.
    View in: PubMed
    Score: 0.004
  150. Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma. Ann Surg Oncol. 1994 Mar; 1(2):111-6.
    View in: PubMed
    Score: 0.003
  151. Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin. Radiother Oncol. 1993 Jun; 27(3):209-15.
    View in: PubMed
    Score: 0.003
  152. Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. Cancer. 1993 Jun 01; 71(11):3690-6.
    View in: PubMed
    Score: 0.003
  153. Low-dose continuous infusion cisplatin combined with external beam irradiation for advanced colorectal adenocarcinoma and unresectable non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1991 Feb; 20(2):351-5.
    View in: PubMed
    Score: 0.003
  154. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys. 1990 Mar; 18(3):710.
    View in: PubMed
    Score: 0.002
  155. Multidisciplinary therapy for esophageal cancer. Adv Surg. 1990; 23:239-60.
    View in: PubMed
    Score: 0.002
  156. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1153-60.
    View in: PubMed
    Score: 0.002
  157. Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 1989 Jul 15; 49(14):4057-61.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.